Waud Capital sells PromptCare's infusion arm to AOM Infusion
What's the deal? Waud Capital PartnersDealroom has a profile for this one. Try Dealroom → has sold the infusion and specialty pharmacy business of The PromptCare Companies to AOM InfusionDealroom has a profile for this one. Try Dealroom →, closing the transaction on October 23, 2026. Terms were not disclosed. PromptCare Infusion provides home and alternate-site infusion therapy and specialty pharmacy services to patients with complex, chronic, and rare conditions.
What each side brings: AOM says the combination pairs its IVIG and immunoglobulin therapies with PromptCare's specialty biologics and bleeding-disorder services. Both companies frame the deal as a way to widen geographic reach and purchasing scale, creating what they call a national, scaled infusion platform.
The backstory: Waud Capital acquired PromptCare in 2021 under a Medication-Based Services campaign led by executive partner Paul Jardina, now the company's chairman and chief executive officer. During Waud's ownership, the infusion business grew revenue fivefold through organic growth and add-on deals such as ARJ Infusion ServicesDealroom has a profile for this one. Try Dealroom →, PICC Lines Plus, and Coastal Infusion ServicesDealroom has a profile for this one. Try Dealroom →.
Over that span, PromptCare Infusion expanded from 19 states to all 50, doubled its pharmacy network to 10 locations, and built 17 ambulatory infusion suites. The sale marks Waud's seventh exit in home and post-acute services and its third in infusion.
What stays behind: Waud is keeping PromptCare's complex respiratory and enteral nutrition services business, which it plans to continue backing.
Why now? The sale lands amid a pickup in home-infusion and specialty-pharmacy dealmaking. Industry data cited by HME News put 2026 deal volume on pace to top 2025, with both segments among the most active.
"Paul and the team have built an exceptional clinical organization, and we believe AOM is the right partner for its next chapter," said Chris Graber, partner and head of healthcare at Waud Capital. Jardina said Waud was "a true partner in every sense, sharing our vision, investing behind our people."
The signal: With the price undisclosed, the deal's financial weight is hard to gauge. But it marks a clear step toward a larger independent infusion platform at a moment when the sector is consolidating fast.
Read more: prnewswire.com
Image credit: Generated with Gemini